Hossam El Benawi: Who Can Safely Stop Anticoagulation after LVT Resolution?
Hossam El Benawi, Senior Clinical Research Fellow of Cardiovascular Medicine at Mayo Clinic, shared on LinkedIn about a recent article he and his colleagues co-authored, published in JACC: Advances, adding:
”Who Might Need Long-Term Anticoagulation After Left Ventricular Thrombus (LVT) Resolution
Much on the optimal anticoagulant for LVT resolution.
However, less is known about management after LVT resolution:
Clinical factors associated with LVT recurrence?
Echo findings predict recurrence?
Should predictors be assessed at the time of LVT diagnosis or resolution?
Most importantly?!!!!: Who can safely STOP AC after LVT resolution?
Our Mayo Clinic multi-site study (Part 2) showed that:
Among 252 patients with LVT resolution, recurrence occurred in (14.3%).
Patients with recurrent LVT were likely to have:
- Ischemic cardiomyopathy (83.3% vs 61.1%, p=0.01)
- Lower LVEF at time of LVT resolution (34.0% ± 12.4 vs 40.0% ± 15.3, p=0.04)
- LV apical aneurysm (25.0% vs 6.5%, p=0.005)
Echo at time of LVT resolution more predictive of recurrence than at diagnosis.
Adjusted Cox Analysis
Factors associated with higher risk of recurrence:
- LV apical aneurysm — HR 3.12 (1.43–6.84)
- Prior ischemic stroke — HR 2.75 (1.22–6.17)
Factors associated with lower risk of recurrence:
- Higher LVEF — HR 0.96 per 1% increase (0.95–0.99)
- Continuation of AC — HR 0.27 (0.13–0.58)
Patients with LV apical aneurysm, prior ischemic stroke, or persistently reduced LVEF benefit from prolonged AC.
The remaining question is:
Who can safely STOP AC after LVT resolution?
Stay tuned for Part 3 of Mayo Clinic multi-site LVT studies, exploring novel bed side score that help to define who can safely STOP AC post resolution?”
Title: Clinical and Echocardiographic Factors Associated With Left Ventricular Thrombus Recurrence
Authors: Kirsten M. Lipps, Hossam Elbenawi, Samuel Heller Jr., Robert D. McBane, Waldemar E. Wysokinski, Ana I. Casanegra, Stanislav Henkin, Thom W. Rooke, Paul W. Wennberg, David A. Liedl, Raymond C. Shields, Damon E. Houghton
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 17, 2026, 17:47Anuoluwapo Oladunjoye: Every Blood Film Has a Story to Tell
-
Jun 17, 2026, 17:46Svetislav Matic: A Patient-Centric Interdisciplinary Approach to Perioperative Bleeding Management
-
Jun 17, 2026, 17:45Paul Breillat: New Insights Into the Role of RIPK1-Mediated Cell Death in VEXAS syndrome
-
Jun 17, 2026, 17:44Konstantin Yenkoyan: New Publication Alert – Autism and Iron Dysregulation
-
Jun 17, 2026, 17:44Ifeanyichukwu Ifechidere: Why Fibrinolysis Matters as Much as Clot Formation
-
Jun 17, 2026, 17:17Soma Agrawal: Transfusion Medicine in India – How Far We Have Come, and How Far We Must Go
-
Jun 17, 2026, 16:52Asayil Basalim: A Milestone in Medical Laboratory Science Training
-
Jun 17, 2026, 16:43Aleksandra Pikula: Canada’s First Women in Midlife Brain Health and Stroke Prevention Program Is Officially Launched
-
Jun 17, 2026, 16:42Alejandro González Veliz: Not Every Acs Patient Needs 12 Months of Dapt